Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
City of Hope Medical Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
BeiGene
Ipsen
Acerta Pharma BV
Amgen
MorphoSys AG
Hackensack Meridian Health
National Institutes of Health Clinical Center (CC)
Amgen
Stanford University
Nordic Nanovector
Ipsen
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
Cancer Research UK
ADC Therapeutics S.A.
Merck Sharp & Dohme LLC
ADC Therapeutics S.A.
Fred Hutchinson Cancer Center
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
University of Washington
GlaxoSmithKline
Dartmouth-Hitchcock Medical Center
Massachusetts General Hospital
Hoffmann-La Roche
Ohio State University Comprehensive Cancer Center